These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28919896)

  • 1. VHH-Based Bispecific Antibodies Targeting Cytokine Production.
    Nosenko MA; Atretkhany KN; Mokhonov VV; Efimov GA; Kruglov AA; Tillib SV; Drutskaya MS; Nedospasov SA
    Front Immunol; 2017; 8():1073. PubMed ID: 28919896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of bioavailability of proinflammatory cytokines produced by myeloid cells.
    Nosenko MA; Atretkhany KN; Mokhonov VV; Vasilenko EA; Kruglov AA; Tillib SV; Drutskaya MS; Nedospasov SA
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S39-S42. PubMed ID: 31779851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokine neutralization at specific cellular source : A new therapeutic paradigm? German Version].
    Kruglov AA; Nedospasov SA
    Z Rheumatol; 2017 Mar; 76(2):163-165. PubMed ID: 28058501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine neutralization at specific cellular source : A new therapeutic paradigm?
    Kruglov AA; Nedospasov SA
    Z Rheumatol; 2017 Mar; 76(Suppl 1):22-24. PubMed ID: 27787607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling.
    Gesiorowski A; Ettich J; Werner J; Wittich C; Pieper S; Padrini G; Behnke K; Floss DM; Lang PA; Moll JM; Scheller J
    J Biol Chem; 2023 Nov; 299(11):105343. PubMed ID: 37838173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and Evaluation of Bispecific Anti-TNF Antibodies Based on Single-Chain V
    Nosenko MA; Atretkhany KN; Mokhonov VV; Chuvpilo SA; Yanvarev DV; Drutskaya MS; Tillib SV; Nedospasov SA
    Methods Mol Biol; 2021; 2248():91-107. PubMed ID: 33185870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression.
    Chen X; Bian Y; Xie Y; Zheng N; Nie K; Liu R; Yan M; Luo H; Wang H; Yang J; Zhang N
    Inflammation; 2021 Aug; 44(4):1620-1628. PubMed ID: 33751358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
    Rajabzadeh A; Rahbarizadeh F; Ahmadvand D; Kabir Salmani M; Hamidieh AA
    Cell J; 2021 Jan; 22(4):502-513. PubMed ID: 32347044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
    Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB
    J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.
    Lipinski B; Unmuth L; Arras P; Becker S; Bauer C; Toleikis L; Krah S; Doerner A; Yanakieva D; Boje AS; Klausz K; Peipp M; Siegmund V; Evers A; Kolmar H; Pekar L; Zielonka S
    MAbs; 2023; 15(1):2236265. PubMed ID: 37469014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The recombinant anti-TNF-α fusion protein ameliorates rheumatoid arthritis by the protective role of autophagy.
    Chen X; Nie K; Zhang X; Tan S; Zheng Q; Wang Y; Chen X; Tang Z; Liu R; Yan M; Liu Z; Lin J; Xu J; Zhang N; Wang H; Yang J
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Engagement of FcγRIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection.
    De Vlieger D; Hoffmann K; Van Molle I; Nerinckx W; Van Hoecke L; Ballegeer M; Creytens S; Remaut H; Hengel H; Schepens B; Saelens X
    Front Immunol; 2019; 10():2920. PubMed ID: 31921179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
    Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
    Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes.
    Strokappe NM; Hock M; Rutten L; Mccoy LE; Back JW; Caillat C; Haffke M; Weiss RA; Weissenhorn W; Verrips T
    Antibodies (Basel); 2019 Jun; 8(2):. PubMed ID: 31544844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE; Tetlow LC
    Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we design a better anti-cytokine therapy?
    Drutskaya MS; Efimov GA; Kruglov AA; Nedospasov SA
    J Leukoc Biol; 2017 Sep; 102(3):783-790. PubMed ID: 28546502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the mucosal immune system in inflammatory bowel disease.
    MacDermott RP
    J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.